According to Neurocrine Biosciences 's latest financial reports the company's total assets are HK$28.94 Billion. A companyโs total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Year | Total assets | Change |
---|---|---|
2024-12-31 | HK$28.87 B | 13.69% |
2023-12-31 | HK$25.39 B | 37.21% |
2022-12-31 | HK$18.50 B | 14.52% |
2021-12-31 | HK$16.16 B | 20.17% |
2020-12-31 | HK$13.44 B | 32.21% |
2019-12-31 | HK$10.17 B | 30.78% |
2018-12-31 | HK$7.77 B | 21.75% |
2017-12-31 | HK$6.38 B | 125.63% |
2016-12-31 | HK$2.83 B | -23.07% |
2015-12-31 | HK$3.67 B | 95.21% |
2014-12-31 | HK$1.88 B | 57.17% |
2013-12-31 | HK$1.19 B | -21.04% |
2012-12-31 | HK$1.51 B | 41.35% |
2011-12-31 | HK$1.07 B | -4.38% |
2010-12-31 | HK$1.12 B | 104.69% |
2009-12-31 | HK$0.54 B | -39.87% |
2008-12-31 | HK$0.91 B | -57.66% |
2007-12-31 | HK$2.15 B | -28.83% |
2006-12-31 | HK$3.03 B | -19.09% |
2005-12-31 | HK$3.74 B | -7.17% |
2004-12-31 | HK$4.03 B | -6.2% |
2003-12-31 | HK$4.30 B | 106.94% |
2002-12-31 | HK$2.07 B | -23.03% |
2001-12-31 | HK$2.70 B |
Company | Total assets | differencediff. | Country |
---|---|---|---|
![]() Repligen
RGEN | HK$22.38 B | -22.66% | ๐บ๐ธ USA |
![]() Royalty Pharma RPRX | HK$138.21 B | 377.49% | ๐ฌ๐ง UK |
![]() Palatin Technologies PTN | HK$29.26 M | -99.90% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | HK$701.66 B | 2,323.97% | ๐บ๐ธ USA |
![]() AbbVie ABBV | HK$1.068 T | 3,592.41% | ๐บ๐ธ USA |
![]() Pfizer PFE | HK$1.632 T | 5,541.13% | ๐บ๐ธ USA |
![]() ANI Pharmaceuticals ANIP | HK$10.14 B | -64.95% | ๐บ๐ธ USA |
![]() Athersys ATHX | HK$58.3 M | -99.80% | ๐บ๐ธ USA |